Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 1921 AL 1935

Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease

Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, Teipel S, Cavedo E, Dos Santos AM, Epelbaum S, Lamari F, Dubois B, Floris R, Garaci F, Bonuccelli U, Hampel H.

Alzheimers Dement. 2017 Sep;13(9):993-1003. doi: 10.1016/j.jalz.2017.01.021. Epub 2017 Mar 3.

Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid

Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B, Freund-Levi Y.

J Alzheimers Dis. 2017;57(2):387-393. doi: 10.3233/JAD-160758.

Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment

Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS.

J Alzheimers Dis. 2017;57(3):645-665. doi: 10.3233/JAD-160907.

Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases

Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H.

Expert Rev Proteomics. 2017 Apr;14(4):285-299. doi: 10.1080/14789450.2017.1304217. Epub 2017 Mar 20.

A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling

Hampel H, O'Bryant SE, Durrleman S, Younesi E, Rojkova K, Escott-Price V, Corvol JC, Broich K, Dubois B, Lista S; Alzheimer Precision Medicine Initiative.

Climacteric. 2017 Apr;20(2):107-118. doi: 10.1080/13697137.2017.1287866. Epub 2017 Feb 9.

T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers

Mietelska-Porowska A, Wojda U.

J Immunol Res. 2017;2017:4626540. doi: 10.1155/2017/4626540. Epub 2017 Feb 15.

Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid

Enche Ady CNA, Lim SM, Teh LK, Salleh MZ, Chin AV, Tan MP, Poi PJH, Kamaruzzaman SB, Abdul Majeed AB, Ramasamy K.

J Neurosci Res. 2017 Oct;95(10):2005-2024. doi: 10.1002/jnr.24048. Epub 2017 Mar 16.

Alzheimer's disease biomarker development: a call to funding bodies

Frisoni GB, Jack CR Jr, Winblad B.

Neurobiol Aging. 2017 Apr;52:117-118. doi: 10.1016/j.neurobiolaging.2016.02.035.

The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues

Porteri C, Albanese E, Scerri C, Carrillo MC, Snyder HM, Martensson B, Baker M, Giacobini E, Boccardi M, Winblad B, Frisoni GB, Hurst S; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:132-140. doi: 10.1016/j.neurobiolaging.2016.07.011.

The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology

Boccardi M, Gallo V, Yasui Y, Vineis P, Padovani A, Mosimann U, Giannakopoulos P, Gold G, Dubois B, Jack CR Jr, Winblad B, Frisoni GB, Albanese E; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:141-152. doi: 10.1016/j.neurobiolaging.2017.01.021.

Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Cerami C, Dubois B, Boccardi M, Monsch AU, Demonet JF, Cappa SF; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:153-166. doi: 10.1016/j.neurobiolaging.2016.03.034.

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024.

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:183-195. doi: 10.1016/j.neurobiolaging.2016.03.033.

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034.

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:214-227. doi: 10.1016/j.neurobiolaging.2016.07.012.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias